Bromide

Bromide

SCHEMBL4295359

Oc1cc(I)ccc1C[P+](c1ccccc1)(c1ccccc1)c1ccccc1.[Br-]

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SNCA P37840 2/20 0.40
HIF1A Q16665 1/20 0.36
ALOX5 P09917 1/20 0.35
APP P05067 1/20 0.34
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
TSHR P16473 1/20 0.33
CYP2C19 P33261 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
BCL2 P10415 1/20 0.32
BCL2L1 Q07817 1/20 0.32
ERN1 O75460 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL4150321 0.87 SNCA (0.40) SNCAHIF1AAPPALDH1A1CYP1A2
Bromide SCHEMBL3146027 0.81 SNCA (0.41) SNCAHIF1AALOX5APPALDH1A1
Bromide SCHEMBL4297579 0.80 SNCA (0.37) SNCAHIF1AALDH1A1CYP1A2CYP2D6
Bromide SCHEMBL3150446 0.80 MEN1 (0.44) SNCAHIF1AALOX5ALDH1A1TSHR
Hydrochloric Acid SCHEMBL8570013 0.79 ALOX5 (0.53) SNCAHIF1AALOX5
Bromide SCHEMBL898427 0.78 HSPA5 (0.48) SNCAHIF1AALDH1A1CYP1A2CYP2D6
Bromide SCHEMBL3154177 0.76 ACP3 (0.38) SNCAALDH1A1CYP2D6TSHR
Bromide SCHEMBL1681292 0.76 POLB (0.50) HIF1AALDH1A1CYP1A2CYP2D6TSHR
SCHEMBL31208250 0.76 HSPA5 (0.50) SNCAHIF1AALDH1A1CYP1A2CYP2D6
Bromide SCHEMBL2160587 0.73 SNCA (0.40) SNCAHIF1AAPPALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-08 US disclosed
US-6194450-B1 KERATINIZATION DISORDERS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 2001-02-27 US disclosed
US-5849798-A Polyaromatic heterocyclic compounds and pharmaceutical/cosmetic compositions comprised thereof CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1998-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands NR3C2, NR3C1, MC2R SNCA 4830/4885HIF1A 3046/4885ALOX5 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.